Amgen announces Sjögren's results as Amgen stock trades flat at EUR 358.63
Published on 10/04/2026 at 18:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen announced positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease on September 22, 2026, according to an Amgen investor release. Amgen stock was unchanged at EUR 358.63 in weekend trading at Lang & Schwarz on October 4, 2026, at 6:31 p.m. CEST, equal to 0.00 percent versus the Lang & Schwarz close of EUR 358.63 on October 2, 2026.
Weekend trading at Lang & Schwarz
The bid was EUR 358.25 and the ask was EUR 359.00 at the quoted time. Xetra remained closed on October 4, 2026. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Amgen stock.
Last Xetra trading day
The Lang & Schwarz close for the last Xetra trading day was EUR 358.63 on October 2, 2026. The October 4, 2026 weekend-trading price was unchanged against that reference.
Amgen's clinical development
Amgen's September 22, 2026 release identified the results as positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease. The investor-relations page also lists the announcement among Amgen's recent news.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
